Proxalutamide Improves Lung Injury in Hospitalized COVID-19 Patients – an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial
Authors: Cadegiani Flávio Adsuara , Fonseca Daniel do Nascimento , Correia Michael do Nascimento , Barros Renan Nascimento , Onety Dirce Costa , Israel Karla Cristina Petruccelli , Guerreiro Emilyn Oliveira , Medeiros José Erique Miranda , Nicolau Raquel Neves , Nicolau Luiza Fernanda Mendonça , Cunha Rafael Xavier , Barroco Maria Fernanda Rodrigues , da Silva Patrícia Souza , Paulain Raysa Wanzeller de Souza , Thompson Claudia Elizabeth , Zimerman Ricardo Ariel , Wambier Carlos Gustavo , Goren Andy 
Published: July 2021

Introduction

Antiandrogens are candidates against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) due to host cell entry inhibition by the suppression of TMPRSS2. Proxalutamide is a nonsteroidal anti-androgen (NSAA) with strong antagonism on androgen receptor (AR) and angiotensin-converting enzyme 2 (ACE2). Efficacy of proxalutamide was previously demonstrated for early COVID-19 outpatients, and also reduction of deaths in hospitalized COVID-19 patients. Whether radiological changes would follow the improvement in clinical outcomes with proxalutamide is not established. The present post-hoc analysis aims to evaluate whether proxalutamide improves lung injury observed through chest computerized tomography (CT) scans.

Methods

This is a post-hoc analysis of the radiological findings of The Proxa-Rescue AndroCoV Trial with all enrolled patients from the three participating institutions of the city of Manaus, Brazil, that had at least two chest CT scans during hospitalization. The quantification of lung parenchyma involvement was performed by blinded radiologists with expertise in analysis of COVID-19 images. A first chest CT scan was performed upon randomization and a second CT scan was performed approximately five days later, whenever feasible. Improvement rate was the first endpoint, and relative and absolute changes between the first and second CT scans were the second endpoints.

Results

Of the 395 patients initially evaluated, 77 and 169 patients from the proxalutamide and placebo arms, respectively, were included (n=246). Baseline characteristics and percentage of lung parenchyma affected in the baseline chest CT scan were similar between groups. In the second chest CT scan, the percentage of lungs affected (Median – IQR) was 35.0% (25.0-57.5%) in the proxalutamide group versus 67.5% (50.0-80.0%) in the placebo group (p < 0.001). The absolute and relative change between the second and first chest CT scans (Median – IQR) were -15.0 percent points (p.p.) (−30.0 – 0.0p.p.) and -25.0% (−50.0 – 0.0%) in the proxalutamide group, respectively, and +15.0p.p. (0.0 - +30.0p.p.) and +32.7% (0.0 - +80.0%) in the placebo group, respectively (p < 0.001 for both absolute and relative changes). The improvement rate, i.e., the percentage of subjects that had improvement from the first to the second CT scan, was 72.3% in the proxalutamide group and 23.1% in the placebo group (p < 0.0001), with an improvement rate ratio (95%CI) of 3.15 (2.32 – 4.28).

Conclusion

Proxalutamide improves lung opacities in hospitalized COVID-19 patients when compared to placebo. (NCT04728802)